The NCPE recommends that niraparib (Zejula®) be considered for reimbursement if cost-effectiveness can be improved relative to existing treatments*.
The NCPE recommends that nivolumab plus ipilimumab be considered for reimbursement if cost-effectiveness can be improved relative to existing treatments*.
Notice to Applicants: Please refer to updated versions of the Rapid Review Submission Template (v2.2), Applicant Submission Template (v2.1), and the Submission Checklist (v1.4) when making submissions.
The NCPE recommends that mogamulizumab (Poteligeo®) not be considered for reimbursement unless cost-effectiveness can be improved relative to existing treatments*.
The NCPE recommends that ravulizumab not be considered for reimbursement unless cost effectiveness can be improved relative to comparator treatments*.
The NCPE recommends that vericiguat not be considered for reimbursement*.
The NCPE recommends that ravulizumab (Ultomiris®), for the treatment of adult patients with PNH, be considered for reimbursement provided certain conditions are met.*
The NCPE recommends that andexanet alfa (Ondexxya®) not be considered for reimbursement unless cost-effectiveness can be improved relative to existing treatments*.
Following assessment of the company submission, the NCPE recommend that enzalutamide (Xtandi®) not be considered for reimbursement unless cost effectiveness can be improved relative to existing treatments*
The NCPE considers empagliflozin to be a cost-effective treatment for adults with symptomatic chronic heart failure with reduced ejection fraction and reimbursement is recommended*.